成人斑秃新型治疗药物系统综述:Janus激酶抑制剂、生物制剂与磷酸二酯酶-4抑制剂
本系统综述检索PubMed与ClinicalTrials.gov,纳入12项随机对照试验,评估JAK抑制剂、生物制剂与PDE-4抑制剂治疗成人斑秃的疗效与安全性。当前数据提示口服JAK抑制剂(巴瑞替尼、利特昔替尼、deuruxolitinib、brepocitinib)可诱导显著毛发再生,不良反应轻至中度;PDE-4抑制剂与生物制剂疗效有限。
要点
- 口服JAK抑制剂(巴瑞替尼、利特昔替尼、deuruxolitinib、brepocitinib)可诱导显著毛发再生,不良反应轻至中度。
- 巴瑞替尼已获美国FDA批准治疗重度斑秃,利特昔替尼与deuruxolitinib获突破性疗法认定。
- PDE-4抑制剂(阿普米司特)与生物制剂(度普利尤单抗、司库奇尤单抗、阿地白介素)目前疗效有限。
核心结论
- 当前数据提示口服JAK抑制剂(巴瑞替尼、利特昔替尼、deuruxolitinib、brepocitinib)是有前景的新型药物类别,可诱导显著毛发再生,不良反应轻至中度。
- PDE-4抑制剂(阿普米司特)与生物制剂(度普利尤单抗、司库奇尤单抗、阿地白介素)目前疗效有限。
- 正在进行及未来的长期研究结果可能阐明新型药物改变斑秃进展的效用。
研究设计与样本
- 系统综述,检索PubMed与ClinicalTrials.gov,共识别106条记录,纳入12项随机对照试验。
- 纳入标准为在成人斑秃患者中评估新型药物(JAK抑制剂、生物制剂、PDE-4抑制剂)的随机对照试验,使用脱发严重程度工具(SALT)评分评估。
- 提取治疗 regimen、疗程、终点、疗效与不良事件信息,并汇总已获批药物的产品专论信息。
主要发现
- 口服JAK抑制剂(巴瑞替尼、利特昔替尼、deuruxolitinib、brepocitinib)可诱导显著毛发再生,不良反应轻至中度。
- 巴瑞替尼近期获美国FDA批准用于治疗重度斑秃。
- 利特昔替尼与deuruxolitinib已获斑秃突破性疗法认定。
- PDE-4抑制剂(阿普米司特)与生物制剂(度普利尤单抗、司库奇尤单抗、阿地白介素)目前疗效有限。
关键数值与推荐
- 纳入12项随机对照试验,使用脱发严重程度工具(SALT)评分评估疗效。
- 巴瑞替尼获美国FDA批准用于重度斑秃。
- 利特昔替尼与deuruxolitinib获斑秃突破性疗法认定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management options for moderate-to-severe alopecia areata (AA) are limited owing to a lack of safe and effective treatments suitable for long-term use. However, newer agents have the potential to induce and maintain hair regrowth in patients with a better side-effects profile compared to systemic steroids or conventional systemic agents. In this article, we conducted a systematic review of newer agents, including Janus kinase (JAK) inhibitors, biologics and phosphodiesterase-4 (PDE-4) inhibitors, for the treatment of AA in adult patients evaluated in randomized controlled trials (RCTs) using the Severity of Alopecia Tool score. A literature search was performed on PubMed and ClinicalTrials.gov, which identified 106 items with 12 RCTs eligible for review. Information regarding the treatment regimen, duration, endpoints, efficacy and adverse events were extracted; product monograph information was also summarized for approved agents with or without indications for AA. Overall, current data suggest the oral JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib, brepocitinib) as a promising new class of agents that can induce significant hair regrowth, with mild to moderate adverse effects. Baricitinib recently received US FDA approval for the treatment of severe AA, while ritlecitinib and deuruxolitinib have received the breakthrough therapy designation for AA. In contrast, PDE-4 inhibitors (apremilast) and the biologics (dupilumab, secukinumab and aldesleukin) appear to have limited efficacy thus far. Results from ongoing and future long-term studies could shed light on the utility of the newer agents in altering the progression of AA.
引用
- Gupta AK, Wang T, Polla Ravi S, et al. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur Acad Dermatol Venereol. 2022. PMID: 36478475. doi:10.1111/jdv.18810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。